First Annual National Lymphoma Awareness Week

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

LOS ANGELES, Calif--The first annual National Lymphoma Awareness Week, sponsored by the Lymphoma Research Foundation of America, is scheduled for October 13 to 19. Members of the Foundation will launch local awareness activities and educational events throughout the week to inform the public about lymphatic cancers.

LOS ANGELES, Calif--The first annual National Lymphoma AwarenessWeek, sponsored by the Lymphoma Research Foundation of America,is scheduled for October 13 to 19. Members of the Foundation willlaunch local awareness activities and educational events throughoutthe week to inform the public about lymphatic cancers.

Actress Jamie Lee Curtis serves as Honorary Chair for AwarenessWeek. Actress Tracy Nelson, daughter of the late singer Rick Nelson,is a Hodgkin's lymphoma survivor and acts as spokesperson forthe Lymphoma Research Foundation. Both actresses have recordeda series of informative public service radio announcements aboutthe disease.

The Lymphoma Research Foundation of America was organized in 1991to raise funds to support research projects seeking to cure lymphomaand find better, safer treatments. To date, 32 research grantshave been awarded.

Internet Site

The Lymphoma Research Foundation also sponsors lymphoma supportgroups, provides programs and resource referrals for patients,publishes a newsletter, and maintains an informative site on theInternet that can be reached at: http://www.lymphoma.org.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content